August 2026 - Defence Therapeutics

Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs

by Defence Therapeutics | Aug 31, 2026 | News Release

Montreal, QC, Canada, August 31st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...

Defence Therapeutics Strengthens Radiopharmaceutical Leadership With Appointment Of Dr. Ryan Simms As Chief Operating Officer And Head Of Radiopharmaceutical Programs

by Defence Therapeutics | Aug 19, 2026 | News Release

Montreal, QC, Canada, August 17, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...

Defence Therapeutics Appoints Dr. Amie Phinney As President And Chief Executive Officer

by Defence Therapeutics | Aug 4, 2026 | News Release

Montreal, QC, Canada, August 4, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...

Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs

Defence Therapeutics Strengthens Radiopharmaceutical Leadership With Appointment Of Dr. Ryan Simms As Chief Operating Officer And Head Of Radiopharmaceutical Programs

Defence Therapeutics Appoints Dr. Amie Phinney As President And Chief Executive Officer

Recent Posts

Recent Comments

Archives

Categories

Meta

Connect with us:
Sign up for news and investor alerts.